Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia

Data presented at the 11th International Myeloma Workshop held in Kos, Greece demonstrates clinical activity of perifosine in combination with bortezomib, dexamethasone and lenalidomide plus dexamethasone, in patients with relapsed/refractory multiple myeloma, and as a single agent in patients with relapsed/refractory Waldenstrom's macroglobulinemia

NEW YORK, June 29, 2007 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that 4 posters were presented at the 11th International Myeloma Workshop demonstrating the clinical activity of KRX-0401 (perifosine) in patients with advanced multiple myeloma and Waldenstrom's macroglobulinemia.

Perifosine is currently being evaluated in 3 ongoing, multi-center clinical studies for patients with relapsed or relapsed/refractory multiple myeloma, including in combination with dexamethasone, in combination with Velcade(R) (bortezomib) and in combination with Revlimid(R) (lenalidomide) plus dexamethasone. Perifosine is also being evaluated in an ongoing phase II single agent study in patients with relapsed and/or refractory Waldenstrom's macroglobulinemia. Data from each of these ongoing studies was presented during the conference and demonstrates perifosine's activity, both as a single agent and as part of a combination, in patients with multiple myeloma and Waldenstrom's macroglobulinemia.

Perifosine in the treatment of Patients with Relapsed/Refractory Multiple Myeloma:

In a poster entitled "A Multicenter Phase I/II Trial of Perifosine (KRX- 0401) + Bortezomib in Relapsed and Refractory Multiple Myeloma in Patients Previously Treated with Bortezomib: Preliminary Results", Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center at the Dana- Farber Cancer Institute in Boston, MA reported an overall response rate (partial response (PR) + minimal response (MR)) of 31%. In 16 evaluable patients treated with pe rifosine plus bortezomib, there were 2 PR's and 1 MR. Two additional MR's were observed on this combination after dexamethasone was added; both of these patients were previously refractory to the combination of bortezomib + dexamethasone without perifosine. Eleven patients remain on study and the phase II portion of the study is now open and enrolling.

A second poster presented by Dr. Richardson, entitled " Perifosine (KRX- 0401) + Low Dose Dexamethasone is Active in Patients with Relapsed and Refractory Multiple Myeloma (MM): Perifosine MM Investigator Group Phase II Multicenter Study Update" demonstrated that 78% of patients treated with perifosine plus low dose dexamethasone had at least stable disease (SD), including 26% that had a PR or MR. Patients continue on study now ranging from 6 months up through 1 year.

Dr. Andrzej Jakubowiak, Director of the myeloma program at the University of Michigan Cancer Center, presented a poster entitled "A Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results. Multiple Myeloma Research Consortium (MMRC) Trial", demonstrating early encouraging results, with 50% of patients achieving a partial response or better.

Commenting on the data, Dr. Richardson stated, "Perifosine's potential in combination with bortezomib, dexamethasone and other novel therapies to overcome drug-resistant multiple myeloma is promising. Our team of investigators, including top centers across the country and now incorporating the considerable resources of the MMRC for one of the trials, is committed to completing enrollment in our studies and evaluating future clinical strategies to improve patient outcome."

Perifosine in the treatment of Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia:

A poster entitled "A Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Wald enstrom's Macroglobulinemia: Preliminary Results" demonstrated single agent activity of perifosine with 36% of patients having a PR or MR. Dr. Irene Ghobrial of the Dana-Farber Cancer Institute, who presented the poster, stated, "We are excited at the efficacy and safety results with perifosine in a patient population for which there is no FDA approved therapy. We look forward to reporting updated results at future meetings."

I. Craig Henderson, MD, President of Keryx Biopharmaceuticals, commented "We are very enthusiastic about the potential of perifosine in the treatment of multiple myeloma and Waldenstrom's macroglobulinemia and the prospects of using perifosine to improve upon the current care for these patients."

In addition to the clinical posters, three pre-clinical posters were presented, as follows:

     Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and

     In Vivo Anti-tumor Activity in Waldenstrom's Macroglobulinemia

      Lead Investigator:   Xavier Leleu, MD, Dana-Farber Cancer Institute,

      Boston, MA

     The Combination of Perifosine with Bortezomib and Rituximab Provides

     Synergistic Anti-tumor Activity in Waldenstrom's Macroglobulinemia

      Lead Investigator:   Xavier Leleu, MD, Dana-Farber Cancer Institute,

      Boston, MA

     Combination of the AKT Inhibitor Perifosine with the HSP90 Inhibitor 17-

     (Dimethylaminoethylamino)-17-Demethoxygeldanamycin (17-DMAG) Has

     Synergistic Activity in tumor cell and its microenvironment in Multiple

     Myeloma (MM)

      Lead Investigator:   Alissa Huston, MD, University of Pittsburgh

      Cancer Center

    Copies of all posters can be obtained from Keryx Biopharmaceuticals, Inc.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. in the United States, Canada and Mexico.

ABOUT KRX-0401 (Perifosine)

KRX-0401 (perifosine) is a novel, first-in-class, oral anticancer agent that modulat es AKT and a number of other key signal transduction pathways, including the MAPK and JNK pathways all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival.

High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft- tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis. High pAkt is often seen in tumors that are resistant to conventional cancer treatments, including radiotherapy, chemotherapy, endocrine therapy, and especially therapy with some of the newer biologicals.

The effects of perifosine on Akt are of particular interest because of 1) the importance of this pathway in the development of most cancers; 2) the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy; and 3) and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. It is plausible that perifosine may be useful in combination to reduce the resistance to other cancer treatments.

To date, over 1,500 patients have been treated with perifosine in trials conducted both in the United States and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not appear to cause myelosuppression (depression of the immune system that may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of perifosine are nausea, vomiting, diarrhea and fatigue, but these are either mild or non-existent in doses that are known to induce tumor regression.

In Phase I/II trials, perifosine has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. Perifosine has shown single agent partial responses or long term disease stabilizations in solid tumors including, renal, hepatocellular, sarcoma and prostate cancer. There is also evidence of activity in hematological malignancies, especially multiple myeloma. Responding patients, including those with stable disease, have been treated for months to more than three years.


Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in- class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisit ion program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future the financial performance and clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete the Phase 1 and Phase 2 clinical trials for KRX-0401; we may not be able to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    Contact:  Lauren Fischer

              Director of Investor Relations

              Keryx Biopharmaceuticals, Inc.


CONTACT: Lauren Fischer, Director of Investor Relations for KeryxBiopharmaceuticals, Inc., +1-212-531-5965

Web site:


Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
2. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:10/8/2015)...  The National Heart, Lung and Blood Institute ... Broad Institute of MIT and Harvard to provide ... well as data to support smaller pilots in ... for Precision Medicine (TOPMed) program and serves ... which will use whole genome sequencing to drive ...
(Date:10/8/2015)... 2015 ... "Natural Language Processing Market for Health ... (Rule-Based, Statistical, & Hybrid NLP Solutions), Region ... Africa, Latin America) - Global Forecast to ... --> ) has announced the ...
(Date:10/8/2015)... Oct. 08 2015 ... "Global API Market Outlook 2020" report ... has announced the addition of the "Global ... offering. --> Research and Markets ( ... "Global API Market Outlook 2020" report ...
Breaking Medicine Technology:
... Aug. 31, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... three upcoming investor conferences.  Dr. Mark A. Sirgo, President ... where he will focus on BDSI,s product pipeline, particularly ... which data from the pivotal Phase 3 efficacy study ...
... 2011 Elbit Imaging Ltd. (NASDAQ: EMITF) ... placed an Investor Relations Presentation relating to its Sources and ... "Investor Relations - Company Presentations -Analysis of Sources and Uses." ... Imaging Ltd. operates in the following principal fields of business: ...
Cached Medicine Technology:
(Date:10/10/2015)... ... 2015 , ... Story Chaser is a one-of-a-kind app that makes ... and inspiring stories and as words drop down and users tap the corresponding word. ... and can be interacted with, making it a more engaging game. Users can use ...
(Date:10/9/2015)... ... ... Doctors on Liens has teamed up with a renowned medical practice, ... to personal injury victims. When personal injury victims suffer major, complex injuries, they ... of conditions ailing them. With the addition of this new group of doctors ...
(Date:10/9/2015)... ... ... A new health tool that helps identify if a sore throat is ... – just in time for the cold and flu season, which the Center for ... the U.S., the real start of cold/flu season is the start of the school ...
(Date:10/9/2015)... ... 2015 , ... Head Over Heels Athletic Arts gymnast, Madelyn Williams, will attend ... Ranch in Huntsville, Texas on October 17-21. , "It's very exciting to be ... and executive director, said. “It's a stepping stone into the U.S. elite system where ...
(Date:10/9/2015)... Orleans, LA (PRWEB) , ... October 09, 2015 ... ... with offices serving New Orleans and the surrounding communities, is initiating a combined ... and medical care for unwanted animals in southern Louisiana. , Animal Rescue ...
Breaking Medicine News(10 mins):
... from exposure to medications, chemicals and other agentsSAN DIEGO, ... taking cold medication or using certain cleaning products can ... A new Web site ( ) ... latest information about the potential risks of exposure to ...
... restore sight, experts suggest , , THURSDAY, March 5 (HealthDay ... in two forms of childhood blindness has been identified ... of the link between the retinal gene SPATA7 and ... because it pinpoints a new retinal metabolic disease pathway ...
... 100 property and casualty insurers closed 2008 with net ... while the top 100 life insurers suffered unprecedented unrealized ... 2008 Top 100 Performance Monitor revealed a 67.7 percent ... industry,s top property and casualty insurers, from $48.8 billion ...
... Americas, Europe and Asia to Realize New Executive ... Tokyo Stock Exchange), a leading medical diagnostics ... announced executive leadership changes at Sysmex Corporate and ... Effective April 1, 2009, Kazuya Obe will ...
... stroke and heart disease are potential complications of type ... Americans. Now research from Tel Aviv University has found ... a risk factor accelerating cognitive decline and dementia. ... TAU,s Sackler School of Medicine, found that people with ...
... 2009 Many doctors don,t offer emergency contraception ... during emergency department visits because of misinformation about ... by The Children,s Hospital of Philadelphia. , ... reduce unintended pregnancy, the study,s authors said. ...
Cached Medicine News:
Symbia T6, a True Point SPECT·CT system, combines a dual-detector variable angle gamma camera with a six slice CT scanner for advanced oncology, neurology, and cardiology applications....
... ACOM.PC turns every standard PC into ... internists, and cardiologists can use their ... access to image data thanks to ... 3 format and the compatible storage ...
... Soarian Cardiovascular Enterprise is a comprehensive ... care continuum from admission to follow-up. ... image acquisition, and diagnostic tools from ... provide a single, longitudinal clinical repository ...
... accurate lesion assessment plays a ... the appropriate stent size and ... (IC3D), a highly precise three-dimensional ... now able to quickly quantify ...
Medicine Products: